Introduction {#s1}
============

Transposons are genetic elements that are found in nearly all living organisms ([@bib19]). They can contribute to the developmental and adaptive regulation of gene expression and are a major source of genetic variation that drives genome evolution ([@bib8]). In humans and other mammals, they comprise about half of the nuclear genome ([@bib55]). The majority of primate-specific sequences that regulate gene expression are derived from transposons ([@bib31]), and transposons are a major source of structural genetic variation in human populations ([@bib56]).

While the majority of genes that encode transposase enzymes tend to become catalytically inactive and their transposon substrates tend to become immobile in the course of organismal evolution, some can maintain their transposition activities ([@bib40]; [@bib45]). In humans, at least one hundred L1 long interspersed repeated sequences (LINEs) actively transpose in human genomes and induce structural variation ([@bib32]), including somatic rearrangements in neurons that may contribute to neuronal plasticity ([@bib17]). The human *Transib*-like transposase RAG1 catalyzes somatic recombination of the V(D)J receptor genes in lymphocytes and is essential for adaptive immunity ([@bib29]). The *Mariner*-derived transposase SETMAR functions in single-stranded DNA resection during DNA repair and replication in human cells and can catalyze DNA transposition in vitro ([@bib40]; [@bib52]).

Among transposase enzymes that can catalyze excision and insertion of transposon sequences, DNA transposases are distinct in their dependence only on the availability of competent genomic substrates and cellular repair enzymes that ligate and repair excision sites, as compared to retrotransposons, which require transcription of the mobilized sequences ([@bib4]). Most DNA transposases utilize an RNase H-like domain with three aspartate or glutamate residues (so-called DDD or DDE motif) that catalyze magnesium-dependent hydrolysis of phosphodiester bonds and strand exchange ([@bib33]; [@bib44]; [@bib14]). The IS4 transposase family, which includes piggyBac transposases, is additionally distinguished by precise excisions without modifications of the transposon flanking sequences ([@bib12]). The piggyBac transposase and its transposon were originally identified as an insertion in lepidopteran *Trichoplusia ni* cells ([@bib21]). The *piggyBac* transposon consists of 13-bp inverted terminal repeats (ITRs) and 19-bp subterminal inverted repeats located 3 and 31 base pairs from the 5′ and 3′ ITRs, respectively ([@bib16]). PiggyBac transposase can mobilize a variety of ITR-flanked sequences and has a preference for integration at TTAA target sites in the host genome ([@bib20]; [@bib3]; [@bib60]; [@bib22]; [@bib16]; [@bib25]; [@bib44]).

Members of the piggyBac superfamily of transposons have colonized a wide range of organisms ([@bib51]), including a recent and likely ongoing invasion of the bat *Myotis lucifugus* ([@bib43]). The human genome contains five paralogous genes derived from *piggyBac* transposases, *PGBD1-5* ([@bib54]; [@bib51]). *PGBD1* and *PGBD2* invaded the common mammalian ancestor, and *PGBD3* and *PGBD4* are restricted to primates, but are all contained as single coding exons, fused in frame with endogenous host genes, such as the Cockayne syndrome B gene (CSB)-PGBD3 fusion ([@bib51]; [@bib47]). Thus far, only the function of *PGBD3* has been investigated. CSB-PGBD3 is capable of binding DNA, including endogenous *piggyBac*-like transposons in the human genome, but has no known catalytic activity, though biochemical and genetic evidence indicates that it may participate in DNA damage response ([@bib1]; [@bib24]).

*PGBD5* is distinct from other human *piggyBac*-derived genes by having been domesticated much earlier in vertebrate evolution approximately 500 million years (My) ago, in the common ancestor of cephalochordates and vertebrates ([@bib51]; [@bib48]). *PGBD5* is transcribed as a multi-intronic but non-chimeric transcript predicted to encode a full-length transposase ([@bib48]). Furthermore, *PGBD5* expression in both human and mouse appears largely restricted to the early embryo and certain areas of the embryonic and adult brain ([@bib51]; [@bib48]). These intriguing features prompted us to investigate whether human PGBD5 has retained the enzymatic capability of mobilizing DNA.

Results {#s2}
=======

Human PGBD5 contains a C-terminal RNase H-like domain that has approximately 20% sequence identity and 45% similarity to the active lepidopteran piggyBac, ciliate piggyMac, and mammalian piggyBat transposases ([Figure 1](#fig1){ref-type="fig"}) ([@bib51]; [@bib2]; [@bib43]). In addition, the human genome contains 2358 sequence elements with similarity to the *piggyBac* transposable elements ([Table 1](#tbl1){ref-type="table"} and [Figure 2A](#fig2){ref-type="fig"}). Specifically, MER75 (MER75, MER75A, MER75B) and MER85 elements show considerably similar ITR sequences as compared to lepidopteran *piggyBac* transposons ([Table 2](#tbl2){ref-type="table"} and [Figure 2B](#fig2){ref-type="fig"}). A total of 328 *piggyBac*-like elements in the human genome have intact ITRs and exhibit duplications of their presumed TTAA target sites ([Table 1](#tbl1){ref-type="table"} and [Figure 2C](#fig2){ref-type="fig"}). We reasoned that even though the ancestral transposon substrates of PGBD5 cannot be predicted due to its very ancient evolutionary origin (∼500 My), preservation of its transposase activity should confer residual ability to mobilize distantly related *piggyBac*-like transposons. To test this hypothesis, we used a synthetic transposon reporter PB-EF1-NEO comprised of a neomycin resistance gene flanked by *T. ni piggyBac* ITRs ([Figure 3B](#fig3){ref-type="fig"}) ([@bib5]; [@bib22]). We transiently transfected human embryonic kidney (HEK) 293 cells, which lack endogenous *PGBD5* expression with the PB-EF1-NEO transposon reporter plasmid in the presence of a plasmid expressing PGBD5, and assessed genomic integration of the reporter using clonogenic assays in the presence of G418 to select cells with genomic integration conferring neomycin resistance ([Figure 3C](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Given the absence of suitable antibodies to monitor PGBD5 expression, we expressed PGBD5 as an N-terminal fusion with the green fluorescent protein (GFP). We observed significant rates of neomycin resistance of cells conferred by the transposon reporter with GFP-PGBD5, but not in cells expressing control GFP or mutant GFP-PGBD5 lacking the transposase domain ([Figure 3C](#fig3){ref-type="fig"}), despite equal expression of all transgenes ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). The efficiency of neomycin resistance conferred by the transposon reporter with GFP-PGBD5 was approximately 4.5-fold less than that of the *T. ni* piggyBac-derived transposase ([Figure 3D](#fig3){ref-type="fig"}), consistent with their evolutionary divergence. These results suggest that human PGBD5 can promote genomic integration of a *piggyBac*-like transposon.10.7554/eLife.10565.003Figure 1.Human PGBD5 is a distinct piggyBac-like transposase.Sequence alignment of piggyBac-like transposases frog Uribo 2, bat piggyBat, lepidopteran piggyBac, and human PGBD5. Catalytic residues conserved among piggyBac transposases are highlighted in red. Human PGBD5 D168, D194, and D386 residues, identified in our study ([Figure 7](#fig7){ref-type="fig"}), are marked in yellow.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.003](10.7554/eLife.10565.003)10.7554/eLife.10565.004Table 1.Summary of annotated human piggyBac-like elements**DOI:** [http://dx.doi.org/10.7554/eLife.10565.004](10.7554/eLife.10565.004)Total piggyBac-like elementsIntact elements[\*](#tblfn1){ref-type="table-fn"}MER75475144MER75A9362MER75B11427MER8590595UCON292400Looper5310[^1][^2]10.7554/eLife.10565.005Figure 2.Human piggyBac-like transposable elements have intact inverted terminal repeat sequences similar to the *T. ni* piggyBac transposon.(**A**) Chromosome ideogram representing the distribution of annotated piggyBac-like elements in the human genome (version hg19). (**B**) Multiple sequence alignment of the piggybac inverted terminal repeat (ITR) sequence with the consensus ITR sequences of the MER75 and MER85 families of piggyBac-like elements. (**C**) Chromosome ideogram representing the distribution of piggyBac-like elements annotated in the human genome (version hg19) with TTAA target site duplication as well as ITR sequences aligning with the consensus (intact ITRs).**DOI:** [http://dx.doi.org/10.7554/eLife.10565.005](10.7554/eLife.10565.005)10.7554/eLife.10565.006Table 2.Sequence identity matrix of the piggyBac inverted terminal repeat sequences and consensus sequences of the MER75 and MER85 human piggyBac-like elements**DOI:** [http://dx.doi.org/10.7554/eLife.10565.006](10.7554/eLife.10565.006)*piggyBacMER75MER85piggyBac*100%----*MER75*53%100%--*MER85*56%63%100%10.7554/eLife.10565.007Figure 3.PGBD5 induces genomic integration of synthetic piggyBac transposons in human cells.(**A**) Schematic of the human PGBD5 protein with its C-terminal transposase homology domain, as indicated. (**B**) Schematic of synthetic transposon substrates used for DNA transposition assays, including transposons with mutant ITR marked by triangles in red, and transposons lacking ITRs marked in blue. (**C**) Representative photographs of crystal violet-stained colonies obtained after G418 selection of HEK293 cells co-transfected with the transposon reporter plasmid along with transposase cDNA expression vectors. (**D**) Quantification of G418-selection clonogenic assays, demonstrating the integration activities of GFP-PGBD5, PGBD5 N-terminus, *T. ni*. piggyBac, and green fluorescent protein (GFP) control (GFP-PGBD5 vs GFP; p = 0.00031). (**E**) Quantification of genomic transposon integration using quantitative PCR of GFP-PGBD5 and GFP expressing cells using intact (black), mutant (red), and deleted (blue) ITR-containing transposon reporters (intact vs mutant ITR; p = 0.00011). Error bars represent standard errors of the mean of 3 biologic replicates.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.007](10.7554/eLife.10565.007)10.7554/eLife.10565.008Figure 3---figure supplement 1.Assay for genomic integration of transposon reporters.Schematic showing the procedure to assay for genomic integration of transposon reporters using G418 selection to clone genomically integrated neomycin resistant cells.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.008](10.7554/eLife.10565.008)10.7554/eLife.10565.009Figure 3---figure supplement 2.GFP-PGBD5, PGBD5 N-terminus, and *T. ni*. piggyBac are equally expressed upon transfection in HEK293 cells.Quantitative RT-PCR specific to GFP-PGBD5, PGBD5 N-terminus, and *T. ni*. piggyBac shows equal mRNA expression of all three transposases (PGBD5 N-terminus p = 0.17, *T. ni.* piggyBac p = 0.092).**DOI:** [http://dx.doi.org/10.7554/eLife.10565.009](10.7554/eLife.10565.009)10.7554/eLife.10565.010Figure 3---figure supplement 3.Sanger sequencing traces of the ITR of the synthetic transposon reporter plasmids.Top to bottom: intact transposon, deleted transposon, and mutant transposon. Black line indicates location of GGG to ATA mutations in mutant transposon ITR.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.010](10.7554/eLife.10565.010)10.7554/eLife.10565.011Figure 3---figure supplement 4.Quantitative assay of genomic integration of transposon reporters.Cells were transfected as described in 'Materials and methods'. Next, cells were expanded and genomic DNA was isolated. Quantitative real-time PCR was performed with primers specific to the transposon sequence as well as to the *TK1* reference gene.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.011](10.7554/eLife.10565.011)10.7554/eLife.10565.012Figure 3---figure supplement 5.Quantitative genomic PCR standard curve for transposon specific primers.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.012](10.7554/eLife.10565.012)

If neomycin resistance conferred by the PGBD5 and the transposon reporter is due to genomic integration and DNA transposition, then this should require specific activity on the transposon ITRs. To test this hypothesis, we generated transposon reporters with mutant ITRs and assayed them for genomic integration ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}). DNA transposition by the piggyBac family transposases involves hairpin intermediates with a conserved 5′-[GGG]{.ul}TTAACCC-3′ sequence that is required for target site phosphodiester hydrolysis ([@bib44]). Thus, we generated reporter plasmids lacking ITRs entirely or containing complete ITRs with 5′-[ATA]{.ul}TTAACCC-3′ mutations predicted to disrupt the formation of productive hairpin intermediates ([@bib44]). To enable precise quantitation of mobilization activity, we developed a quantitative genomic PCR assay using primers specific for the transposon reporter and the endogenous human *TK1* gene for normalization ([Figure 3---figure supplements 4, 5](#fig3s4 fig3s5){ref-type="fig"}). In agreement with the results of the clonogenic neomycin resistance assays, we observed efficient genomic integration of the donor transposons in cells transfected by GFP-PGBD5 as compared to the minimal signal observed in cells expressing GFP control ([Figure 3E](#fig3){ref-type="fig"}). Deletion of transposon ITRs from the reporter reduced genomic integration to background levels ([Figure 3E](#fig3){ref-type="fig"}). Consistent with the specific function of *piggyBac* family ITRs in genomic transposition, mutation of the terminal GGG sequence in the ITR significantly reduced the integration efficiency ([Figure 3E](#fig3){ref-type="fig"}). These results indicate that specific transposon ITR sequences are required for PGBD5-mediated DNA transposition.

DNA transposition by piggyBac superfamily transposases is distinguished from most other DNA transposon superfamilies by the precise excision of the transposon from the donor site and preference for insertion in TTAA sites ([@bib5]; [@bib22]). To determine the structure of the donor sites of transposon reporters mobilized by PGBD5, we isolated plasmid DNA from cells 2 days after transfection, amplified the transposon reporter using PCR, and determined its sequence using capillary Sanger sequencing ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Similar to the hyperactive *T. ni* piggyBac, cells expressing GFP-PGBD5, but not those expressing GFP control vector, exhibited robust excision of ITR-flanked transposon with apparently precise repair of the donor plasmid ([Figure 4A,B](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These results suggest that PGBD5 is an active cut-and-paste DNA transposase.10.7554/eLife.10565.013Figure 4.PGBD5 precisely excises piggyBac transposons.(**A**) Representative agarose electrophoresis analysis of PCR-amplified PB-EF1-NEO transposon reporter plasmid from transposase-expressing cells, demonstrating efficient excision of the ITR-containing transposon by PGBD5, but not GFP or PGBD5 N-terminus mutant lacking the transposase domain. *T. ni* piggyBac serves as positive control. (**B**) Representative Sanger sequencing fluorogram of the excised transposon, demonstrating precise excision of the ITR and associated duplicated TTAA sequence, marked in red, demonstrating integrations of transposons (green) into human genome (blue) with TTAA insertion sites and genomic coordinates, as marked.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.013](10.7554/eLife.10565.013)10.7554/eLife.10565.014Figure 4---figure supplement 1.Schematic of transposon excision assay.Cells were transfected as described in 'Materials and methods'. Next, DNA was isolated. PCR was performed with primers specific to sequences flanking the transposon.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.014](10.7554/eLife.10565.014)

To validate chromosomal integration and determine the location and precise structure of the insertion of the reporter transposons in the human genome, we isolated genomic DNA from G418-resistant HEK293 cells following transfection with PGBD5 and PB-EF1-NEO and amplified the genomic sites of transposon insertions using flanking sequence exponential anchored (FLEA) PCR, a technique originally developed for high-efficiency analysis of retroviral integrations ([@bib50]). We adapted FLEA-PCR for the analysis of genomic DNA transposition by using unique reporter sequence to prime polymerase extension upstream of the transposon ITR into the flanking human genome, followed by reverse linear extension using degenerate primers, and exponential amplification using specific nested primers to generate chimeric amplicons suitable for massively parallel single-molecule Illumina DNA sequencing ([Figure 5](#fig5){ref-type="fig"}) ([@bib27]). This method enabled us to isolate specific portions of the human genome flanking transposon insertions, as evidenced by the reduced yield of amplicons isolated from control cells lacking transposase vectors or expressing GFP ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). To identify the sequences of the transposon genomic insertions at single-base pair resolution, we aligned reads obtained from FLEA-PCR Illumina sequencing to the human hg19 reference genome and synthetic transposon reporter, and identified split reads that specifically span both ([Figure 5](#fig5){ref-type="fig"}). These data have been deposited to the Sequence Read Archive (<http://www.ncbi.nlm.nih.gov/sra/>, accession number SRP061649, [@bib63]), with the processed and annotated data available from the Dryad Digital Repository ([@bib28]).10.7554/eLife.10565.015Figure 5.Schematic of transposon-specific flanking sequence exponential anchored--polymerase chain reaction amplification (FLEA-PCR) and massively parallel single molecule sequencing assay for mapping and sequencing transposon insertions.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.015](10.7554/eLife.10565.015)

To infer the mechanism of genomic integration of transposon reporters, we analyzed the sequences of the insertion loci to determine integration preferences at base-pair resolution and identify potential sequence preferences. We found that transposon amplicons isolated from cells expressing GFP-PGBD5, but not those isolated from GFP control cells, were significantly enriched for TTAA sequences, as determined by sequence entropy analysis ([@bib10]) ([Figure 6A](#fig6){ref-type="fig"}). To discriminate between potential DNA transposition at TTAA target sites and alternative mechanisms of chromosomal integration, we classified genomic insertions based on target sites containing TTAA and those containing other sequence motifs ([Table 3](#tbl3){ref-type="table"}). Consistent with the DNA transposition activity of PGBD5, we observed significant induction of TTAA-containing insertions in cells expressing GFP-PGBD5 and transposons with intact ITRs, as compared to control cells expressing GFP, or to cells transfected with GFP-PGBD5 and mutant ITR transposons ([Table 3](#tbl3){ref-type="table"}). Sequence analysis of split reads containing transposon-human junction at TTAA sites revealed that, in almost every case examined (*n* = 65 out of 66), joining between TTAA host and transposon DNA occurred precisely at the GGG/CCC terminal motif of the donor transposon ITR ([Figure 6C](#fig6){ref-type="fig"}), in agreement with its requirement for efficient DNA transposition ([Figure 3E](#fig3){ref-type="fig"}). Consistent with the genome-wide transposition induced by PGBD5, we identified transposition events in all human chromosomes, including both genic and intergenic loci ([Figure 6B](#fig6){ref-type="fig"}). Thus, PGBD5 can mediate canonical cut-and-paste DNA transposition of *piggyBac* transposons in human cells.10.7554/eLife.10565.016Figure 6.PGBD5 induces DNA transposition in human cells.(**A**) Analysis of the transposon integration sequences, demonstrating TTAA preferences in integrations in cells expressing GFP-PGBD5, but not GFP control. X-axis denotes nucleotide sequence logo position, and y-axis denotes information content in bits. (**B**) Circos plot of the genomic locations PGBD5-mobilized transposons plotted as a function of chromosome number and transposition into genes (red) and intergenic regions (gray). (**C**) Alignment of representative DNA sequences of identified genomic integration sites.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.016](10.7554/eLife.10565.016)10.7554/eLife.10565.017Figure 6---figure supplement 1.Representative agarose gel image of amplicons from flanking sequence exponential anchored--polymerase chain reaction amplification (FLEA-PCR).Arrow indicated expected size of degenerate anchor primer amplicons.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.017](10.7554/eLife.10565.017)10.7554/eLife.10565.018Table 3.Analysis of transposon integration sequences in human genomes induced by PGBD5**DOI:** [http://dx.doi.org/10.7554/eLife.10565.018](10.7554/eLife.10565.018)Intact transposonMutant transposonTTAA ITRNon-ITRTTAA ITRNon-ITRTransposase GFP-PGBD582% (65)^†^18% (14)11% (4)^‡^89% (33) GFP Control17% (2)83% (10)40% (27)60% (40)[^3][^4]

Requirement for transposon substrates with specific ITRs, their precise excision, and preferential insertion into TTAA-containing genomic locations is all consistent with the preservation of PGBD5\'s DNA transposase activity in human cells. Like other cut-and-paste transposases, piggyBac superfamily transposases are thought to utilize a triad of aspartate or glutamate residues to catalyze phosphodiester bond hydrolysis, but the catalytic triad of aspartates previously proposed for *T. ni* piggyBac is apparently not conserved in the primary sequence of PGBD5 ([Figure 1](#fig1){ref-type="fig"}) ([@bib51]; [@bib33]; [@bib44]; [@bib46]). Thus, we hypothesized that distinct aspartic or glutamic acid residues may be required for DNA transposition mediated by PGBD5. To test this hypothesis, we used alanine-scanning mutagenesis and assessed transposition activity of GFP-PGBD5 mutants using quantitative genomic PCR ([Figure 7](#fig7){ref-type="fig"} and [Figure 7---figure supplements 1--3](#fig7s1 fig7s2 fig7s3){ref-type="fig"}). This analysis indicated that simultaneous alanine mutations of D168, D194, and D386 reduced apparent transposition activity to background levels, similar to that of GFP control ([Figure 7A](#fig7){ref-type="fig"}). We confirmed that the mutant GFP-PGBD5 proteins have equivalent stability and expression as the wild-type protein in cells by immunoblotting against GFP ([Figure 7B](#fig7){ref-type="fig"}). Phylogenetic analysis of vertebrate piggyBac homologs from *Danio rerio*, *Python bivittatus*, *Xenopus tropicalis*, *Gallus gallus*, *Mus musculus*, and *Homo sapiens* showed that PGBD5 proteins are divergent from other piggyBac-like proteins ([Figure 8](#fig8){ref-type="fig"}) and include conservation of functionally important D168, D194, and D386 residues that distinguish them from lepidopteran piggyBac and human PGBD1-4 ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). These results suggest that PGBD5 represents a distinct member of the evolutionarily ancient piggyBac-like family of DNA transposases.10.7554/eLife.10565.019Figure 7.Structure-function analysis of PGBD5-induced DNA transposition using alanine scanning mutagenesis.(**A**) Quantitative PCR analysis of genomic integration activity of alanine point mutants of GFP-PGBD5, as compared to wild-type and GFP control-expressing cells. D168A, D194A, and D386A mutants (red) exhibit significant reduction in apparent activity (Asterisks denote statistical significance: p = 0.00011, p = 0.000021, p = 0.000013 vs GFP-PGBD5, respectively). Dotted line marks threshold at which less than 1 transposon copy was detected per haploid human genome. Error bars represent standard errors of the mean of 3 biological replicates. (**B**) Western immunoblot showing equal expression of GFP-PGBD5 mutants, as compared to wild-type GFP-PGBD5 (green). β-actin (red) serves as loading control.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.019](10.7554/eLife.10565.019)10.7554/eLife.10565.020Figure 7---figure supplement 1.Sanger sequencing trances of pRecLV103-GFP-PGBD5 D\>A and E\>A mutants (D168A, D175A, E188A, D192A, D194A, E203A, E205A, E236A).**DOI:** [http://dx.doi.org/10.7554/eLife.10565.020](10.7554/eLife.10565.020)10.7554/eLife.10565.021Figure 7---figure supplement 2.Sanger sequencing trances of pRecLV103-GFP-PGBD5 D\>A and E\>A mutants (D241A, D244A, E284A, E285A, E287A, D303A, E365A, E373A).**DOI:** [http://dx.doi.org/10.7554/eLife.10565.021](10.7554/eLife.10565.021)10.7554/eLife.10565.022Figure 7---figure supplement 3.Sanger sequencing trances of pRecLV103-GFP-PGBD5 D\>A and E\>A mutants (D386A, D387A, D425A, E439A, E444A, E449A, D450A).**DOI:** [http://dx.doi.org/10.7554/eLife.10565.022](10.7554/eLife.10565.022)10.7554/eLife.10565.023Figure 8.*PGBD5* homologs are divergent from other *piggyBac* genes in vertebrates.Phylogenetic reconstruction of the evolutionary relationships among piggyBac transposase-derived genes in vertebrates, demonstrating the PGBD5 homologs represent a distinct subfamily of piggyBac-like derived genes. Scale bar represents Grishin distance.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.023](10.7554/eLife.10565.023)10.7554/eLife.10565.024Figure 8---figure supplement 1.PGBD5 glutamic acid resitues D168, D194, and D386 are conserved across species.Clustal O alignment of PGBD5 proteins across species (*Danio rerio, Xenopus tropicalis, Homo sapiens, Mus musculus, Gallus gallus, Python bivittatus*). D168, D194, and D386 residues are highlighted in yellow.**DOI:** [http://dx.doi.org/10.7554/eLife.10565.024](10.7554/eLife.10565.024)

Discussion {#s3}
==========

Our current findings indicate that human PGBD5 is an active *piggyBac* transposase that can catalyze DNA transposition in human cells. DNA transposition by PGBD5 requires its C-terminal transposase domain and depends on specific ITRs derived from the lepidopteran *piggyBac* transposons ([Figure 3](#fig3){ref-type="fig"}). DNA transposition involves transesterification reactions mediated by DNA hairpin intermediates ([@bib44]). Consistent with the requirement of intact termini of the piggyBac, Tn10, and Mu transposons ([@bib16]), elimination or mutation of the terminal GGG nucleotides from the transposon substrates also abolishes the transposition activity of PGBD5 ([Figure 3](#fig3){ref-type="fig"}). PGBD5-induced DNA transposition is precise with preference for insertions at TTAA genomic sites ([Figure 4](#fig4){ref-type="fig"}). Since our analysis was limited to ectopically expressed PGBD5 fused to GFP and episomal substrates derived from lepidopteran *piggyBac* transposons, it is possible that endogenous PGBD5 may exhibit different activities on chromatinized substrates in the human genome.

Current structure-function analysis indicates that PGBD5 requires three aspartate residues to mediate DNA transposition ([Figure 7](#fig7){ref-type="fig"}), but its transposase domain appears to be distinct from other piggyBac transposase enzymes with respect to its primary sequence ([Figure 1](#fig1){ref-type="fig"} and [Figure 8](#fig8){ref-type="fig"}) ([@bib33]). Thus, the three aspartate residues required for efficient DNA transposition by PGBD5 may form a catalytic triad that functions in phosphodiester bond hydrolysis, similar to the DDD motif in other *piggyBac* family transposases, or alternatively may contribute to other steps in the transposition reaction, such as synaptic complex formation, hairpin opening, or strand exchange ([@bib16]; [@bib33]; [@bib44]). In addition, we find that alanine mutations of the three required aspartate residues in the PGBD5 transposase domain significantly reduce but do not completely eliminate genomic integration of the transposon reporters ([Figure 7](#fig7){ref-type="fig"}). This could reflect residual catalytic activity despite these mutations, or that PGBD5 expression may affect other mechanisms of DNA integration in human cells.

The evolutionary conservation of the transposition activity of PGBD5 suggests that it may have hitherto unknown biologic functions among vertebrate organisms. DNA transposition is a major source of genetic variation that drives genome evolution, with some DNA transposases becoming extinct and others domesticated to evolve exapted functions. The evolution of transposons\' activities can be highly variable, with some organisms such as *Zea mays* undergoing continuous genome remodeling and recent twofold expansion through endogenous retrotransposition, *Drosophila* and *Saccharomyces* owing over half of their known spontaneous mutations to transposons, and primate species including humans exhibiting relative extinction of transposons ([@bib19]).

Indeed, transposase-derived genes domesticated in humans have evolved to have endogenous functions other than genomic transposition per se. For example, human RAG1 is a domesticated *Transib* transposase that has retained its active transposase domain, and can transpose ITR-containing transposons in vitro, but catalyzes somatic recombination of immunoglobulin and T-cell receptor genes in lymphocytes across signal sequences that might be derived from related transposons ([@bib35]; [@bib23]). Human SETMAR is a *Mariner*-derived transposase with a divergent DDN transposase domain that has retained its endonuclease activity and functions in double-strand DNA repair by non-homologous end joining ([@bib40]). The human genome encodes over 40 other genes derived from DNA transposases ([@bib55]; [@bib19]), including *THAP9* that was recently found to mobilize transposons in human cells with as of yet unknown function ([@bib41]). RAG1, THAP9, and PGBD5 are, to our knowledge, the only human proteins with demonstrated transposase activity in human cells.

The distinct biochemical and structural features of PGBD5 indicated by our findings are consistent with its unique evolution and function among human *piggyBac*-derived transposase genes ([@bib51]; [@bib48]). *PGBD5* exhibits deep evolutionary conservation predating the origin of vertebrates, including a preservation of genomic synteny across lancelet, lamprey, teleosts, and amniotes ([@bib48]). This suggests that while PGBD5 likely derived from an autonomous mobile element, this ancestral copy was immobilized early in evolution and PGBD5 can probably no longer mobilize its own genomic locus, at least in germ line cells. The human genome contains several thousands of miniature inverted repeat transposable elements (MITEs) with similarity to *piggyBac* transposons ([Figure 2](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}) ([@bib51]; [@bib19]). CSB-PGBD3 can bind to the *piggyBac*-derived *MER85* elements in the human genome ([@bib1]; [@bib24]). Similarly, it is possible that PGBD5 can act *in trans* to recognize and mobilize one or several related MITEs in the human genome. Recently, single-molecular maps of the human genome have predicted thousands of mobile element insertions, and the activity of PGBD5 or other endogenous transposases may explain some of these novel variants ([@bib6]; [@bib49]).

Given that both human RAG1 and ciliate piggyMac domesticated transposases catalyze the elimination of specific genomic DNA sequences ([@bib29]; [@bib2]), it is reasonable to hypothesize that PGBD5\'s biological function may similarly involve the excision of as of yet unknown ITR-flanked sequences in the human genome or another form of DNA recombination. Since DNA transposition by *piggyBac* family transposases requires substrate chromatin accessibility and DNA repair, we anticipate that additional cellular factors are required for and regulate PGBD5 functions in cells. Likewise, just as RAG1-mediated DNA recombination of immunoglobulin loci is restricted to B lymphocytes, and rearrangements of T-cell receptor genes to T lymphocytes, potential DNA rearrangements mediated by PGBD5 may be restricted to specific cell types and developmental periods.

*PGBD5* localizes to the cell nucleus and is expressed during embryogenesis and neurogenesis, but its physiological function is not yet known ([@bib48]). Generation of molecular diversity through DNA recombination during nervous system development has been a long-standing hypothesis ([@bib13]; [@bib61]). The recent discovery of somatic retrotransposition in human neurons ([@bib9]; [@bib18]; [@bib59]), combined with our finding of DNA transposition activity by human PGBD5, which is highly expressed in neurons, suggests that additional mechanisms of somatic genomic diversification may contribute to vertebrate nervous system development.

Because DNA transposition is inherently topological and orientation of transposons can affect the arrangements of reaction products ([@bib7]), potential activities of PGBD5 can depend on the arrangements of accessible genomic substrates, leading to both conservative DNA transposition involving excision and insertion of transposon elements, as well as irreversible reactions such as DNA elimination and chromosomal breakage-fusion-bridge cycles, as originally described by [@bib42]. Finally, given the potentially mutagenic activity of active DNA transposases, we anticipate that unlicensed activity of PGBD5 and other domesticated transposases can be pathogenic in specific disease states, particularly in cases of aberrant chromatin accessibility, such as cancer.

Materials and methods {#s4}
=====================

Reagents {#s4-1}
--------

All reagents were obtained from Sigma--Aldrich (St. Louis, MO, United States) if not otherwise specified. Synthetic oligonucleotides were obtained from Eurofins MWG Operon (Huntsville, AL, United States) and purified by HPLC.

Cell culture {#s4-2}
------------

HEK293 and HEK293T were obtained from the American Type Culture Collection (ATCC, Manassas, Virginia, United States). The identity of all cell lines was verified by STR analysis and lack of *Mycoplasma* contamination was confirmed by Genetica DNA Laboratories (Burlington, NC, United States). Cell lines were cultured in DMEM supplemented with 10% fetal bovine serum and 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere at 37°C and 5% CO~2~.

Plasmid constructs {#s4-3}
------------------

Human PGBD5 cDNA (Refseq ID: NM_024554.3) was cloned as a GFP fusion into the lentiviral vector pReceiver-Lv103-E3156 (GeneCopoeia, Rockville, MD, United States). *piggyBac* ITRs (5′-TTAACCCTAGAAAGATAATCATATTGTGACGTACGTTAAAGATAATCATGTGTAAAATTGACGCATG-3′ and 5′-CATGCGTCAATTTTACGCAGACTATCTTTCTAGGGTTAA-3′), as originally cloned by Malcolm Fraser et al. ([@bib16]; [@bib25]), were cloned into PB-EF1-NEO to flank IRES-driven neomycin resistance gene, as obtained from System Biosciences (Mountain View, CA, United States). Plasmid encoding the hyperactive *T. ni* piggyBac transposase, as originally generated by Nancy Craig et al. ([@bib38]), was obtained from System Biosciences. Site-directed PCR mutagenesis was used to generate mutants of PGBD5 and *piggyBac*, according to manufacturer\'s instructions (Agilent, Santa Clara, CA, United States). Plasmids were verified by restriction endonuclease mapping and Sanger sequencing and deposited in Addgene. Lentivirus packaging vectors psPAX2 and pMD2.G were obtained from Addgene ([@bib11]).

Cell transfection {#s4-4}
-----------------

HEK293 cells were seeded at a density of 100,000 cells per well in a 6-well plate and transfected with 2 μg of total plasmid DNA, containing 1 μg of transposon reporter (PB-EF1-NEO or mutants) and 1 μg of transposase cDNA (pRecLV103-GFP-PGBD5 or mutants) using Lipofectamine 2000, according to manufacturer\'s instructions (Life Technologies, CA, United States). After 24 hr, transfected cells were trypsinized and re-plated for functional assays.

Quantitative RT-PCR {#s4-5}
-------------------

Upon transfection, cells were cultured for 48 hr and total RNA was isolated using the RNeasy Mini Kit, according to manufacturer\'s instructions (Qiagen, Venlo, Netherlands). cDNA was synthesized using the SuperScript III First-Strand Synthesis System (Invitrogen, Waltham, MA, United States). Quantitative real-time PCR was performed using the KAPA SYBR FAST PCR polymerase with 20 ng template and 200 nM primers, according to the manufacturer\'s instructions (Kapa Biosystems, Wilmington, MA, United States). PCR primers are listed in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. Ct values were calculated using ROX normalization using the ViiA 7 software (Applied Biosystems).

Neomycin resistance colony formation assay {#s4-6}
------------------------------------------

Upon transfection, cells were seeded at a density of 1000 cells per 10-cm dish and selected with G418 sulfate (2 mg/ml) for 2 weeks. Resultant colonies were fixed with methanol and stained with crystal violet.

Transposon excision assay {#s4-7}
-------------------------

Upon transfection, cells were cultured for 48 hr and DNA was isolated using the PureLink Genomic DNA Mini Kit, according to manufacturer\'s instructions (Life Technologies). Reporter plasmid sequences flanking the neomycin resistance cassette transposons were amplified using hot start PCR with an annealing temperature of 57°C and extension time of 2 min, according to the manufacturer\'s instructions (New England Biolabs, Beverly, MA, United States) using the Mastercycler Pro thermocycler (Eppendorf, Hamburg, Germany). PCR primers are listed in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. The PCR products were resolved using agarose gel electrophoresis and visualized by ethidium bromide staining. Identified gel bands were extracted using the PureLink Quick Gel Extraction Kit (Invitrogen) and Sanger sequenced to identify excision products.

Quantitative PCR assay of genomic transposon integration {#s4-8}
--------------------------------------------------------

Upon transfection, cells were selected with puromycin (5 μg/ml) for 2 days to eliminate non-transfected cells. After selection, cells were expanded for 10 days without selection and genomic DNA isolated using PureLink Genomic DNA Mini Kit (Life Technologies). Quantitative real-time PCR was performed using the KAPA SYBR FAST PCR polymerase with 20 ng template and 200 nM primers, according to the manufacturer\'s instructions (Kapa Biosystems). PCR primers are listed in [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}. Ct values were calculated using ROX normalization using the ViiA 7 software (Applied Biosystems). We determined the quantitative accuracy of this assay using analysis of serial dilution PB-E1-NEO plasmid as reference ([Figure 3---figure supplement 5](#fig3s5){ref-type="fig"}).

FLEA-PCR {#s4-9}
--------

To amplify genomic transposon integration sites, we modified FLEA-PCR ([@bib50]), as described in [Figure 5](#fig5){ref-type="fig"} ([@bib27]). First, linear extension PCR was performed using 2 μg of genomic DNA and 100 nM biotinylated linear primer using the Platinum HiFidelity PCR mix, according to manufacturer\'s instructions (Invitrogen Corp.). Linear extension parameters for PCR were: 95°C (45 s), 62°C (45 s), 72°C (3 min) for 30 cycles. Reaction products were purified by diluting the samples in a total volume of 200 μl of nuclease-free water and centrifugation using the Amicon Ultra 0.5 ml 100 K at 12,000×*g* for 10 min at room temperature (EMD Millipore, Billerica, MA, United States) purification. Retentate was bound to streptavidin ferromagnetic beads on a shaker at room temperature overnight (Dynal, Oslo, Norway). Beads were washed with 40 μl of washing buffer (Kilobase binder kit; Dynal), then water, then 0.1 N NaOH, and finally with water again.

To anneal the anchor primer, washed beads were resuspended in a total volume of 20 μl containing 5 μM anchor primer, 500 nM dNTP, and T7 DNA polymerase buffer (New England Biolabs). Samples were placed in a heating block pre-heated to 85°C and allowed to passively cool to 37°C. Once annealed, 10 units of T7 DNA polymerase (New England Biolabs) was added and the mixtures were incubated for 1 hr at 37°C. Next, the beads were washed five times in water.

To exponentially amplify the purified products, beads were resuspended in a total volume of 50 μl containing 500 nM of exponential and Transposon1 primers and the Platinum HiFidelity PCR mix. PCR was performed with the following parameters: 95°C for 5 min, followed by 35 cycles of 95°C for 45 s, 62°C for 45 s, and 72°C for 3 min. PCR products were purified using the Invitrogen PCR purification kit (Invitrogen Corp.). Second nested PCR was performed using 1/50th of the first exponential PCR product as template using the Platinum HiFidelity PCR with 500 nM of exponential and Transposon2 primers. PCR was performed with the following parameters: 35 cycles of 95°C for 45 s, 62°C for 45 s, and 72°C for 3 min. Final PCR products were purified using the Invitrogen PCR purification kit, according to the manufacturer\'s instructions (Invitrogen Corp.).

Sequencing of transposon reporter integration sites {#s4-10}
---------------------------------------------------

Equimolar amounts of purified FLEA-PCR amplicons were pooled, as measured using fluorometry with the Qubit instrument (Invitrogen) and sized on a 2100 BioAanalyzer instrument (Agilent Technologies). The sequencing library construction was performed using the KAPA Hyper Prep Kit (Kapa Biosystems) and 12 indexed Illumina adaptors from IDT (Coralville, IO, United States), according to the manufacturer\'s instructions.

After quantification and sizing, libraries were pooled for sequencing on a MiSeq (pooled library input at 10 pM) on a 300/300 paired end run (Illumina, San Diego, CA, United States). An average of 575,565 paired reads were generated per sample. The duplication rate varied between 56 and 87%. Because of the use of FLEA-PCR amplicons for DNA sequencing, preparation of Illumina sequencing libraries is associated with the formation of adapter dimers ([@bib30]). We used cutadapt to first trim reads to retain bases with quality score \>20, then identify reads containing adapter dimers and exclude them from further analyses (parameters -q 20 -b P7 = \<P7_index\> -B P5 = \<P5_index\> -discard; where \<P7_index\> is the P7 primer adapter with the specific barcode for each library, and \<P5_index\> is the generic P5 adapter sequence: GATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGCCGTATCATT) ([@bib39]). Anchor primer sequences were then trimmed from the reads retained using cutadapt (-g\^GTGGCACGGACTGATCNNNNNN). Filtered and trimmed reads were mapped to a hybrid reference genome consisting of the hg19 full chromosome sequences and the PB-EF1-NEO plasmid sequence using bwa-mem using standard parameters ([@bib37]). Mapped reads were then analyzed with LUMPY using split read signatures ([@bib36]), and insertion loci were identified using the called variants flagged as interchromosomal translocations (BND) between the plasmid sequence and the human genome. Breakpoints were resolved to base-pair accuracy using split read signatures when possible. Insertion loci were taken with 10 flanking base pairs and aligned with MUSCLE to establish consensus sequence ([@bib36]). Genomic distribution of insertion loci was plotted using ChromoViz (<https://github.com/elzbth/ChromoViz>). All analysis scripts are available from Zenodo ([@bib26]).

Lentivirus production and cell transduction {#s4-11}
-------------------------------------------

Lentivirus production was carried out as described in [@bib34]. Briefly, HEK293T cells were transfected using TransIT with 2:1:1 ratio of the pRecLV103 lentiviral vector, and psPAX2 and pMD2.G packaging plasmids, according to manufacturer\'s instructions (TransIT-LT1, Mirus, Madison, WI, United States). Virus supernatant was collected at 48 and 72 hr post-transfection, pooled, filtered, and stored at −80°C. HEK293T cells were transduced with virus particles at a multiplicity of infection of five in the presence of 8 μg/ml hexadimethrine bromide. Transduced cells were selected for 2 days with puromycin (5 μg/ml).

Western blotting {#s4-12}
----------------

To analyze protein expression by Western immunoblotting, 1 million transduced cells were suspended in 80 μl of lysis buffer (4% sodium dodecyl sulfate, 7% glycerol, 1.25% beta-mercaptoethanol, 0.2 mg/ml Bromophenol Blue, 30 mM Tris-HCl, pH 6.8). Cells suspensions were lysed using Covaris S220 adaptive focused sonicator, according to the manufacturer\'s instructions (Covaris, Woburn, CA, United States). Lysates were cleared by centrifugation at 16,000×*g* for 10 min at 4°C. Clarified lysates (30 μl) were resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electroeluted using the Immobilon FL PVDF membranes (Millipore). Membranes were blocked using the Odyssey Blocking buffer (Li-Cor, Lincoln, Nebraska) and blotted using the mouse and rabbit antibodies against GFP (1:500, clone 4B10) and β-actin (1:5000, clone 13E5), respectively, both obtained from Cell Signaling Technology (Beverly, MA, United States). Blotted membranes were visualized using goat secondary antibodies conjugated to IRDye 800CW or IRDye 680RD and the Odyssey CLx fluorescence scanner, according to manufacturer\'s instructions (Li-Cor).

Multiple sequence alignment analysis of DNA and protein sequences {#s4-13}
-----------------------------------------------------------------

The transposon annotation of the human genome (assembly hg19) was downloaded from the UCSC website (<http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/rmsk.txt.gz>) and converted to the GFF3 annotation format. The sequences of the elements in the piggyBac-like MER75, MER75A, MER75B, MER85, UCON29, and LOOPER families were extracted with 50 flanking base pairs using fastaFromBed from the BedTools genome analysis suite (<http://bedtools.readthedocs.org>). The set of sequences for each family was aligned using MUSCLE using standard parameters ([@bib15]). ITR sequences for each family were defined as terminal sequences conserved amongst all family members measured using multiple sequence alignments. We used a cutoff of 70% similarity to determine the fist position of the ITR in the alignment. The multiple sequence alignments were then manually curated to identify the set of 'intact' elements defined by containing both the TTAA target site duplication as well as both 3′ and 5′ ITRs aligning without gaps with the consensus ITR sequence. Multiple sequence alignment of the ITR sequences was also performed with MUSCLE, and the sequence identity matrix calculated using SIAS (<http://imed.med.ucm.es/Tools/sias.html>), with the following measure of identity:$$Identity = 100 \ast \left( \frac{Number~of~Identical~Residues}{Length~of~shortest~sequence} \right).$$

Chromosome ideograms were made using the NCBI\'s Genome Decoration Tool (<http://www.ncbi.nlm.nih.gov/genome/tools/gdp/>). Multiple sequence alignment of protein sequences was done using Clustal Omega ([@bib58]; [@bib53]). Pairwise BLAST alignments-based Grishin\'s sequence distance analysis was done using BLAST (<http://blast.ncbi.nlm.nih.gov/>) and MEGA6 using standard parameters ([@bib57]).

Statistical analysis {#s4-14}
--------------------

Statistical significance values were determined using two-tailed non-parametric Mann--Whitney tests for continuous variables, and two-tailed Fisher exact test for discrete variables.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled "Genomic DNA transposition induced by human PGBD5" for peer review at *eLife*. Your submission has been evaluated by James Manley (Senior Editor), a Reviewing Editor, and two reviewers. One of the two reviewers, Harmit Malik, has agreed to share his identity.

The reviewers have discussed the reviews with one another and the Senior Editor has drafted this decision to help you prepare a revised submission.

In this well-performed study, the authors reveal the rather surprising conservation of catalytic activity of PGBD5, a *piggyBac*-derived domesticated transposase gene that is one of the oldest conserved domestication events in vertebrates. One of the reviewers commented that: "this is definitely a result of high importance in the field. Not only is it surprising but it opens the possibility of as yet unanticipated DNA transposition in vertebrates that is itself of high interest." However, while the results are interesting, there are a number of questions that need to be addressed before the paper will be suitable for publication in *eLife*.

Essential revisions:

1\) What and where are the sequences in the human genome that the authors indicate are "*piggyBac* transposon-like"? The authors imply that the human *piggyBac* transposons are not identifiable based on an evolutionary argument, but given the conservation of the TIRs of the *Trichoplusia ni* transposon, how were putative human *piggyBac* transposons attempted to be found? How similar are the terminal and sub-terminal inverted repeats in human DNA elements thought to be related to *piggyBac* elements relative to the *Trichoplusia ni piggyBac* elements?

2\) PGBD5 is revealed to have a rather non-canonical catayltic triad of aspartate residues compared to the original well characterized *piggyBacs*. Rather surprisingly, even the dependence on these newly identified aspartates is not obligatory for catalytic activity. The authors (we think correctly) interpret this to imply a rather divergent *piggyBac* lineage gave rise to PGBD5 -- however, there is no attempt to identify such lineages from sequence databases and use them to refine ideas about catalytic site conservation. The data presented is quite convincing about the lack of conservation of canonical aspartates, but rather sparse on the evolutionary history and conservation of PGBD5-like domains. This should not be a difficult task and we would ask you to include phylogenetic analysis and multiple alignments to augment the alanine scanning results presented.

3\) The current title of the paper should be revised to indicate that the human PGBD5 protein is mobilizing the heterologous *piggyBac* transposon DNA element from *Trichoplusia ni*.

Other issues to address:

1\) Given that conservation of the terminal inverted repeats in *the Trichoplusia ni piggyBac* transposon and the statement in the paper that there are human DNA sequences related to *piggybac* transposons in the human genome, have the author tried to see if PGBD5 can mobilize the human sequences?

2\) The authors say that the catalytic DDD triad of residues in PGBD5 was not easy to find. In fact, a previous paper from the Weiner group claimed, using phylogenetic evidence, that the PGBD5 protein would be inactive. The alignment shown indicates a lack of acidic residues in common other *PiggyBac* transposases. Did the authors look at the paper from Susan Wessler to see if their catalytic residues coincide with their extensive phylogenetic predictions (The catalytic domain of all eukaryotic cut-and-paste transposase superfamilies. Yuan YW, Wessler SR. Proc Natl Acad Sci U S A. 2011 May 10;108(19):7884--9)?

3\) Based on the mutagenesis performed in the paper, are the three D residues identified in the present work found in the protein sequences of any of the other related human PGBD1-4 proteins or in any of the primate-specific *PiggyBac* family members? The authors might indicate, on the supplemental figure showing the canonical catalytic residues for the insect *PiggyBac* transposases, where the three DDD residues found by the alanine mutagenesis shown in this paper.

4\) The assays shown indicate that the human PGBD5 protein is less active than the cognate *Trichoplusia ni* transposase in mobilizing the *piggyBac* transposon. Can the authors give a better quantitation of these data and state that explicitly in the text? Based on the figure, it looks like ∼ 4--fold less active.

5\) What is the biological consequence of the PGBD5 mediated transposition? We believe this is outside the scope of the study, but could be presented with additional information about expression patterns of this gene, for instance in mouse development.

10.7554/eLife.10565.027

Author response

Essential revisions:

*1) What and where are the sequences in the human genome that the authors indicate are "*piggyBac *transposon-like"? The authors imply that the human* piggyBac *transposons are not identifiable based on an evolutionary argument, but given the conservation of the TIRs of the* Trichoplusia ni *transposon, how were putative human* piggyBac *transposons attempted to be found? How similar are the terminal and sub-terminal inverted repeats in human DNA elements thought to be related to* piggyBac *elements relative to the* Trichoplusia ni piggyBac *elements?*

*piggyBac*-like sequences in the human genome have previously been annotated in RepBase. We have now extended this annotation by direct analysis of *piggyBac*-like *MER75*, *MER75a*, *MER75b*, *MER85*, *UCON29* and *Looper* sequences. These results indicate that human *piggyBac*-like sequences are present across the entire genome (revised [Figure 2A](#fig2){ref-type="fig"}), and include a subset of elements with intact inverted terminal repeats and TTAA target site duplications (revised [Figure 2B-C](#fig2){ref-type="fig"} and revised [Table 1](#tbl1){ref-type="table"}). While the human *piggyBac*-like elements exhibit sufficient similarity in their inverted terminal repeats to the lepidopteran *piggyBac* transposon to permit these analyses, their sequences are apparently too divergent to enable identification of sub-terminal repeats and sequence elements by pair-wise sequence comparisons alone. The manuscript text has been revised accordingly (Results, first paragraph).

*2) PGBD5 is revealed to have a rather non-canonical catayltic triad of aspartate residues compared to the original well characterized* piggyBacs*. Rather surprisingly, even the dependence on these newly identified aspartates is not obligatory for catalytic activity. The authors (we think correctly) interpret this to imply a rather divergent* piggyBac *lineage gave rise to PGBD5 -- however, there is no attempt to identify such lineages from sequence databases and use them to refine ideas about catalytic site conservation. The data presented is quite convincing about the lack of conservation of canonical aspartates, but rather sparse on the evolutionary history and conservation of PGBD5-like domains. This should not be a difficult task and we would ask you to include phylogenetic analysis and multiple alignments to augment the alanine scanning results presented.*

As suggested, we have now compared the protein sequences of vertebrate *piggyBac*-derived genes. This phylogenetic analysis indicates that zebrafish, python, frog, chicken, mouse and human PGBD5 homologs constitute a divergent subfamily of *piggyBac*-like transposases among vertebrates (revised [Figure 8](#fig8){ref-type="fig"}). Consistent with our findings of the functional requirement of D168, D194, and D386 residues for PGBD5's DNA transposition activity, these three residues are conserved among all examined vertebrate PGBD5 homologs, but not among other *piggyBac*-derived genes such as human PGBD1-4 and lepidopteran *piggyBac* (revised [Figure 8](#fig8){ref-type="fig"}). We have revised the manuscript text accordingly (Results, last paragraph).

*3) The current title of the paper should be revised to indicate that the human PGBD5 protein is mobilizing the heterologous* piggyBac *transposon DNA element from* Trichoplusia ni*.*

We firmly believe in reporting research findings accurately and without hyperbole. For this reason we made sure to explicitly specify the observed activity of PGBD5 in the Abstract, and note that PGBD5 acts on "DNA sequences containing inverted terminal repeats with similarity to *piggyBac* transposons." We struggled with devising a title that would comprehensively express the manuscript's findings while remaining succinct. We considered the following alternatives but found that they are either awkward and cumbersome (*"*Human PGBD5 is a DNA transposase that can mobilize heterologous *piggyBac transposons* into the human genome*"*), or do not sufficiently communicate our findings ("The human PGBD5 domesticated transposase is catalytically active"). We believe that the current title reporting that human PGBD5 can induce transposition into the human genome is the best solution to this need.

Other issues to address:

*1) Given that conservation of the terminal inverted repeats in the* Trichoplusia ni piggyBac *transposon and the statement in the paper that there are human DNA sequences related to* piggybac *transposons in the human genome, have the author tried to see if PGBD5 can mobilize the human sequences?*

In spite of extensive efforts to identify endogenous *piggyBac*-like elements that may serve as substrates for PGBD5, we have not been able to do so using sequence analysis given their extensive divergence in the human genome (revised [Figure 2](#fig2){ref-type="fig"} and [Tables 1--2](#tbl1 tbl2){ref-type="table"}). We have considered a pooled library screen to identify potential substrates based on transposition efficiency, but have decided that this would be beyond the scope of the current manuscript.

*2) The authors say that the catalytic DDD triad of residues in PGBD5 was not easy to find. In fact, a previous paper from the Weiner group claimed, using phylogenetic evidence, that the PGBD5 protein would be inactive. The alignment shown indicates a lack of acidic residues in common other* PiggyBac *transposases. Did the authors look at the paper from Susan Wessler to see if their catalytic residues coincide with their extensive phylogenetic predictions (The catalytic domain of all eukaryotic cut-and-paste transposase superfamilies. Yuan YW, Wessler SR. Proc Natl Acad Sci U S A. 2011 May 10;108(19):7884--9)?*

We have now carried out additional phylogenetic analysis of vertebrate *piggyBac*-derived genes, demonstrating conservation of the functionally required D168, D194, and D386 residues among all examined PGBD5 homologs in vertebrates, and their phylogenetic divergence from other *piggyBac*-like transposases (see response to comment \#2 above). As pointed out by the referees, Yuan and Wessler published an extensive sequence analysis of eukaryotic transposase-derived genes, including lepidopteran *piggyBac*, but did not examine the vertebrate PGBD5 specifically.

*3) Based on the mutagenesis performed in the paper, are the three D residues identified in the present work found in the protein sequences of any of the other related human PGBD1-4 proteins or in any of the primate-specific* PiggyBac *family members? The authors might indicate, on the supplemental figure showing the canonical catalytic residues for the insect* PiggyBac *transposases, where the three DDD residues found by the alanine mutagenesis shown in this paper.*

We have revised [Figure 1](#fig1){ref-type="fig"} and include new [Figure 8](#fig8){ref-type="fig"} to highlight these residues, as compared to other *piggyBac*-like transposase-derived genes.

*4) The assays shown indicate that the human PGBD5 protein is less active than the cognate* Trichoplusia ni *transposase in mobilizing the* piggyBac *transposon. Can the authors give a better quantitation of these data and state that explicitly in the text? Based on the figure, it looks like ∼ 4*--*fold less active.*

We compared the apparent activity of human PGBD5 to the hyperactive version of the lepidopteran *piggyBac*: "The efficiency of neomycin resistance conferred by the transposon reporter with GFP-PGBD5 was approximately 4.5--fold less than that of the *T. ni* piggyBac-derived transposase" (Results, first paragraph).

5\) What is the biological consequence of the PGBD5 mediated transposition? We believe this is outside the scope of the study, but could be presented with additional information about expression patterns of this gene, for instance in mouse development.

We share the referees' interest in this question, and are actively investigating the physiologic and pathogenic functions of PGBD5. The manuscript includes a discussion of our considerations of this problem (Discussion, paragraphs five to eight).

[^1]: Denotes elements with intact ITR sequences that align with the consensus without gaps and contain a TTAA target site duplication.

[^2]: ITR, inverted terminal repeat.

[^3]: Cells expressing GFP-PGBD5 and intact transposons exhibit significantly higher frequency of genomic integration as compared to either GFP control, or GFP-PGBD5 with mutant transposons, with 82% (65 out of 79) of sequences demonstrating DNA transposition of ITR transposons into TTAA sites (†p = 1.8 × 10-5). Mutation of the transposon ITR significantly reduces ITR-mediated integration, with only 11% (4 out of 37) of sequences (‡p = 0.0016). Numbers in parentheses denote absolute numbers of identified insertion sites.

[^4]: GFP, green fluorescent protein; ITR, inverted terminal repeat.
